Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16237477,bioavailability,THC bioavailability averages 30%.,Pharmacokinetics of cannabinoids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16237477/),%,30,132223,DB00486,Nabilone
,16237477,peak plasma level,"With a 3.55% THC cigarette, a peak plasma level of 152±86.3 ng/mL occured approximately 10 min after inhalation.",Pharmacokinetics of cannabinoids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16237477/),[ng] / [ml],152,132224,DB00486,Nabilone
,16237477,bioavailable,"Oral THC, on the other hand, is only 4% to 12% bioavailable and absorption is highly variable.",Pharmacokinetics of cannabinoids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16237477/),%,4,132225,DB00486,Nabilone
,16237477,plasma elimination half-life,"Nabilone is well absorbed and the pharmacokinetics, although variable, appear to be linear from oral doses of 1 mg to 4 mg (these doses show a plasma elimination half-life of approximately 2 h).",Pharmacokinetics of cannabinoids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16237477/),h,2,132226,DB00486,Nabilone
,872500,half-life,"The absorbed drug disappeared from plasma rather rapidly (half-life, approximately 2 hr), evidently due to extensive tissue distribution and rapid metabolism.","Physiologic disposition of nabilone, a cannabinol derivative, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872500/),h,2,169231,DB00486,Nabilone
exceeds,872500,half-life of total radioactivity,The metabolites of nabilone persist in plasma for extended periods (half-life of total radioactivity exceeds 20 hr).,"Physiologic disposition of nabilone, a cannabinol derivative, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872500/),h,20,169232,DB00486,Nabilone
,22680341,apparent t(1/2),"Oral THC apparent t(1/2) was 72-80 min, t(max) was 39-56 min and C(max) 2.92-4.69 ng ml(-1) .",Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22680341/),min,72-80,207011,DB00486,Nabilone
,22680341,t(max),"Oral THC apparent t(1/2) was 72-80 min, t(max) was 39-56 min and C(max) 2.92-4.69 ng ml(-1) .",Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22680341/),min,39-56,207012,DB00486,Nabilone
,22680341,C(max),"Oral THC apparent t(1/2) was 72-80 min, t(max) was 39-56 min and C(max) 2.92-4.69 ng ml(-1) .",Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22680341/),[ng] / [ml],2.92-4.69,207013,DB00486,Nabilone
